<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621006</url>
  </required_header>
  <id_info>
    <org_study_id>CAS UC</org_study_id>
    <nct_id>NCT04621006</nct_id>
  </id_info>
  <brief_title>The Contact Activation System and Ulcerative Colitis</brief_title>
  <official_title>The Contact Activation System and Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sydvestjysk Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sygehus Lillebaelt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sydvestjysk Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to describe alterations in the contact activation system during active and&#xD;
      inactive ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a part of a Ph.d. project anchored at the Department of Medical Gastroenterology&#xD;
      and the Unit of Thrombosis Research at the University Hospital of Southern Denmark - Esbjerg.&#xD;
&#xD;
      A total of 47 participants with active disease are to be followed in a prospective cohort&#xD;
      study for 26 weeks. The study will describe differences between active and inactive disease.&#xD;
&#xD;
      Data obtained from all participants are&#xD;
&#xD;
        -  demographics&#xD;
&#xD;
        -  assessment of quality of life (SIBDQ questionnaire)&#xD;
&#xD;
        -  assessment of disease activity (SCCAI questionnaire, PRO 2 questionnaire, endoscopic&#xD;
           Mayo score, histologic score by the Nancy index, c-reactive peptide and fecal&#xD;
           calprotectin)&#xD;
&#xD;
        -  assessment of the concentration and activity of the contact activation system proteins&#xD;
&#xD;
        -  assessment of misfolded alpha-1-antitrypsin.&#xD;
&#xD;
        -  assessment of ER stress (GRP78/BiP)&#xD;
&#xD;
      The endoscopic and histologic assessment serve as the gold standard.&#xD;
&#xD;
      Medias analyzed are blood, stool and colonic tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coagulation Factor XII (FXII)</measure>
    <time_frame>26 weeks</time_frame>
    <description>FXII concentration in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prekallikrein (PK)</measure>
    <time_frame>26 weeks</time_frame>
    <description>PK concentration in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma kallikrein (PKa) generation</measure>
    <time_frame>26 weeks</time_frame>
    <description>The amount of PKa generated upon FXII activation in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Native high-molecular-weight-kininogen (HK)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of native HK in plasma, stool and cell lysate. Colonic biopsies are stained to detect the presence of native HK.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PKa cleaved High-molecular-weight-kininogen (HK)</measure>
    <time_frame>26 weeksa in plasma, stool and cell lysate.</time_frame>
    <description>The amount of HK cleaved by PKa in plasma, stool and cell lysate. Colonic biopsies are stained to detect the presence of PKa cleaved HK.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue kallikrein (TKa) cleaved High-molecular-weight-kininogen (HK)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The amount of HK cleaved by TKa in plasma, stool and cell lysate. Colonic biopsies are stained to detect the presence of TKa cleaved HK.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C1-esterase inhibitor (C1 Inh)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of C1 Inh in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polymerized alpha-1-antitrypsin (AAT)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of polymerized AAT in plasma, stool and cell lysate. Colonic biopsies are stained to detect polymerized AAT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elastase</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of elastase in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin generation</measure>
    <time_frame>26 weeks</time_frame>
    <description>The amount of thrombin generated upon FXII activation in plasma, stool and cell lysate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simple Clinical Colitis Activity Index questionnaire (SCCAI)</measure>
    <time_frame>26 weeks</time_frame>
    <description>SCCAI score range: 0-21. Score &gt;5 indicate disease activity. The higher score the more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome 2 questionnaire (PRO2)</measure>
    <time_frame>26 weeks</time_frame>
    <description>PRO2 score range: 0-6. The higher score the more disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Quality of life assessed in relation to disease activity. Score range: The higher score, the worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayo score</measure>
    <time_frame>26 weeks</time_frame>
    <description>Endoscopic assessment of disease severity. Score range: 0-3. The higher score the worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nancy Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Histologic assessment of disease severity in colonic biopsies. Score range: Grad 0-4. The higher score the worse severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive peptide (CRP)</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of CRP in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>26 weeks</time_frame>
    <description>The concentration of calprotectin in stool.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>UC group</arm_group_label>
    <description>Patients with active ulcerative colitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Consecutively assessment of the disease activity</intervention_name>
    <description>Analyzes listed in the detailed study description is measured consecutively. SIBDQ and lower endoscopy are performed at only 3 visits. The remaining analyzes are performed at each visit.</description>
    <arm_group_label>UC group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, stool and fixated colonic tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are enrolled from the Department of Medical Gastroenterology at the Hospital of&#xD;
        Southwest Jutland, Region of Southern Denmark, Denmark&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfill diagnostic criteria of ulcerative colitis&#xD;
&#xD;
          -  SCCAI score ≥ 5&#xD;
&#xD;
          -  Mayo Endoscopic Subscore ≥ 1&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Most understand written and oral information in Danish&#xD;
&#xD;
          -  Informed consent must be given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Infection at inclusion&#xD;
&#xD;
          -  Any existing disease at inclusion:&#xD;
&#xD;
               -  liver disease or defect in CAS&#xD;
&#xD;
               -  inflammatory rheumatologic or dermatologic disease&#xD;
&#xD;
               -  cardiovascular or renal disease&#xD;
&#xD;
               -  immunodeficiency or hematologic diseases&#xD;
&#xD;
               -  malignancies&#xD;
&#xD;
          -  Medication with&#xD;
&#xD;
               -  Systemic corticosteroids at inclusion&#xD;
&#xD;
               -  ACE-inhibitor&#xD;
&#xD;
               -  Acetylsalicylic acid/NSAID&#xD;
&#xD;
               -  Warfarin, Phenprocoumon, NOAC and heparins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten L Halling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Gastroenterology, University Hospital of Southern Denmark - Esbjerg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten Lee Halling, M.D.</last_name>
    <phone>+4523313821</phone>
    <email>morten.halling@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Gastroenterology, University Hospital of Southern Denmark</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Halling, M.D.</last_name>
      <phone>+4523313821</phone>
      <email>morten.halling@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sydvestjysk Hospital</investigator_affiliation>
    <investigator_full_name>Morten Lee Halling</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Misfolded protein</keyword>
  <keyword>Coagulation Factor XII</keyword>
  <keyword>Kallikrein</keyword>
  <keyword>High Molecular Weight Kininogen</keyword>
  <keyword>The contact activation system</keyword>
  <keyword>Endoplasmatic reticulum stress</keyword>
  <keyword>Misfolded alpha-1-antitrypsin</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

